Released Nov 9, 2026, after the close
10-Q filed Nov 9, 2026, 40 days after period end · 0001104659-26-124503
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$144.76M | -$65.71M | -$33.98M | -$23.86M |
| EPS Diluted | -$0.66 | -$0.37 | -$0.20 | -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Structure Therapeutics Inc. · CIK 1888886 · Engraved from SEC EDGAR
Structure Therapeutics reported a net loss of $144.8 million for the third quarter of 2026, compared with $65.7 million for the same period in 2025.¶1
R&D expenses were $134.6 million for the third quarter of 2026, compared with $59.0 million a year earlier, and G&A expenses were $21.8 million, compared with $14.8 million.¶2¶3
Cash, cash equivalents and short-term investments totaled $1.2 billion as of September 30, 2026, compared with $1.3 billion as of June 30, 2026, expected to fund operations through the end of 2028.¶4
The Phase 3 ACCOMPLISH program for aleniglipron initiated in August 2026, with topline data expected in the second half of 2028.¶5¶6¶7¶8
Dosing has begun in the multiple ascending dose portion of the ACCG-2671 trial, with topline data expected in the first half of 2027.¶9¶10¶11